What question did this study set out to answer?

The aim is to evaluate new targeted therapies for pediatric HLH to improve outcomes and reduce drug toxicity.

Targeting the cytokine storm: new therapies in the treatment of paediatric haemophagocytic lymphohistiocytosis

View Full Paper

Ask AI

Bookmark

Authors

Review highlights new targeted therapies for pediatric HLH, suggesting improved patient outcomes.

The aim is to evaluate new targeted therapies for pediatric HLH to improve outcomes and reduce drug toxicity.
Reviewed current treatment strategies for primary and secondary HLH.
Discussed emerging therapies including emapalumab, alemtuzumab, and ruxolitinib.
Evaluated evidence from small, non-randomized trials.
Emapalumab, alemtuzumab, and ruxolitinib demonstrate promising results.
Widespread use of these therapies is limited due to the nature of existing trials.
Collaboration for further clinical trials is essential to compare new therapies with conventional treatments.

Cahill et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark